...and Incyte Corp. (NASDAQ:INCY) have INCAGN1876, and Leap Therapeutics Inc. (NASDAQ:LPTX) has several partnerships testing TRX518...

...TILs or ≥1.35% CD8+ T cells in the tumor center. 2986 Leap Therapeutics Inc. (NASDAQ:LPTX) TRX518...
...blood of solid tumor patients, reduction of circulating Treg numbers was a pharmacodynamic marker of TRX518...

...homolog 1 (DKK1) , is in Phase I/II testing for esophageal cancer and cholangiocarcinoma. Leap’s TRX518...

...dickkopf homolog 1 (DKK1), is in Phase I/II testing for esophageal cancer and cholangiocarcinoma. Leap's TRX518...

...a single dose of 0.0001-8 mg/kg IV TRX518 led to 4 cases of stable disease. TRX518...
...American Society of Clinical Oncology meeting in Chicago. Leap Therapeutics Inc. , Cambridge, Mass. Product: TRX518...

...against Dickkopf homolog 1 (DKK1) in Phase I/II for esophageal cancer and cholangiocarcinoma. GITR had TRX518...
...Leap came after his firm reviewed clinical data for DKN-01 in esophageal cancer and evaluated TRX518's...

...NASDAQ:AGEN); Incyte Corp. (NASDAQ:INCY) Cancer Preclin AlphaVax Inc. Cancer Preclin GITR Inc. Cancer Ph I (TRX518...

...last week. GITR Inc. says it has the first-in-class molecule in the space. The biotech's TRX518...

...In a mouse model of cancer, a murine analog of TRX518 as monotherapy and in combination...
...Keystone Symposia on Antibodies as Drugs meeting in Keystone. Tolerx Inc. , Cambridge, Mass. Product: TRX518...

...TRX518 over 18 weeks in up to 40 patients. Tolerx Inc. , Cambridge, Mass. Product: TRX518...